SAN DIEGO--(BUSINESS WIRE)--
Haeggquist & Eck, LLP, a leading shareholder rights litigation firm, is investigating whether certain directors and officers of AmerisourceBergen Corporation (“Amerisource” or the “Company”) (ABC) breached their fiduciary duties to Amerisource and its shareholders. If you are a Amerisource shareholder, you are encouraged to contact Amber Eck at (619) 342-8000 or firstname.lastname@example.org for additional information.
AmerisourceBergen sources and distributes pharmaceutical products in the United States and internationally. In September 2017, the company's AmerisourceBergen Specialty Group unit pleaded guilty to a misdemeanor related to the sale of syringes containing drugs for cancer patients, double billing, and providing kickbacks to doctors, and paid $260 million in criminal fines and forfeitures. The Company also entered a five-year corporate integrity agreement to ensure compliance with federal health care rules.
On October 1, 2018, the U.S. Department of Justice announced that the Company will pay $625 million to resolve civil fraud charges over related conduct, bringing AmerisourceBergen's total payments to $885 million over its repackaging and distribution of pre-filled syringes that were not approved by the U.S. Food and Drug Administration.
What You Can Do
If you are a Amerisource shareholder, you may have claims against the Company’s directors and officers. If you wish to discuss this notice or if you have questions about this notice or your legal rights, please contact Amber Eck at 619-342-8000 or e-mail her at email@example.com. There is no cost or obligation to you.
Haeggquist & Eck, LLP is a nationally recognized leader in shareholder rights law. The firm represents individual investors in shareholder derivative lawsuits, and members of the firm have helped shareholders recover more than $1 billion of value for themselves and the companies in which they have invested.
This release constitutes attorney advertising. Past results do not guarantee a similar outcome.